Pellepharm, Inc.

275 Middlefield Road
Suite 100
Menlo Park
California
94025
United States

Email: info@pellepharm.com

Show jobs for this employer

About Pellepharm, Inc.


PellePharm is developing patidegib, a novel hedgehog pathway inhibitor, to treat basal cell carcinomas (BCCs), including those in Gorlin Syndrome, a devastating rare genetic skin disease. The company is focused on developing and commercializing this treatment to reduce the burden of disease and improve quality of life by potentially reducing invasive and painful surgeries and the scarring that often accompanies them. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently being studied in two phase 2 clinical trials for the treatment of BCCs and Gorlin Syndrome.

YEAR FOUNDED:

2012

LEADERSHIP:

Founders: Ervin Epstein, Philip Beachy and Jean Tang

CMO: Karl Beutner

3 articles with Pellepharm, Inc.